Journal
NATURE NEUROSCIENCE
Volume 12, Issue 9, Pages 1129-U13Publisher
NATURE RESEARCH
DOI: 10.1038/nn.2372
Keywords
-
Categories
Funding
- Parkinson's Disease Society UK [G-4063, G-0713, G-0715]
- Royal Society and Wellcome Trust [081987]
- MRC Centre for Developmental and Biomedical Genetics [G070091]
- Wellcome Trust [GR077544AIA]
- Light Microscopy Facility
- Medical Research Council [G0700091B] Funding Source: researchfish
- Parkinson"
- s UK [G-0715, G-0713] Funding Source: researchfish
Ask authors/readers for more resources
Mutations in PINK1 and PARK2 cause autosomal recessive parkinsonism, a neurodegenerative disorder that is characterized by the loss of dopaminergic neurons. To discover potential therapeutic pathways, we identified factors that genetically interact with Drosophila park and Pink1. We found that overexpression of the translation inhibitor Thor (4E-BP) can suppress all of the pathologic phenotypes, including degeneration of dopaminergic neurons in Drosophila. 4E-BP is activated in vivo by the TOR inhibitor rapamycin, which could potently suppress pathology in Pink1 and park mutants. Rapamycin also ameliorated mitochondrial defects in cells from individuals with PARK2 mutations. Recently, 4E-BP was shown to be inhibited by the most common cause of parkinsonism, dominant mutations in LRRK2. We also found that loss of the Drosophila LRRK2 homolog activated 4E-BP and was also able to suppress Pink1 and park pathology. Thus, in conjunction with recent findings, our results suggest that pharmacologic stimulation of 4E-BP activity may represent a viable therapeutic approach for multiple forms of parkinsonism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available